Purpose: The effect of omeprazole on the oral bioavailability and urinary exposure of the Depomed formulation of extended-release(ER) ciprofloxacin was studied.
Methods: A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography.
Results: Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria.
Conclusion: Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin.Introduction

Ciprofloxacin is a fluoroquinolone antimicrobial agent with a broad spectrum of activity against both gram-negative and gram-positive bacteria.[1,2] One oral extended-release (ER) formulation of ciprofloxacin hydrochloride (Proquin XR, Depomed, Inc.) delivers 90% of a 500-mg dose (of ciprofloxacin) over a six-hour period to the upper-gastrointestinal (GI) tract, where ciprofloxacinis best absorbed.[3] This formulation contains polymeric excipients that cause the tablet to enlarge in the stomach by absorbing water from the gastric fluid. The tablet relies on a combination of size and the physiology of the fed stomach to delay gastric emptying and provide extended release of ciprofloxacin. Omeprazoleis a gastric proton-pump inhibitor that blocks acid production in the stomach, resulting in decreased gastric acidity and potentially altered drug absorption.[4,5] Although the bioavailability of conventional, immediate-release ciprofloxacin is not affected by coadministration with omeprazole,[6] the absorption and systemic availability of ciprofloxacin from another ER formulation (Cipro XR, Bayer) are reduced when the drug is coadministered with omeprazole.[7] Hence, the objective of this study was to determine the effect of omeprazole on the oral bioavailability and urinary excretion of the Depomed formulation of ER ciprofloxacin.
This is a part of article Imipenem-Cilastatin or Ampicillin-Sulbactam or Cipro-Ciprofloxacin. Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog

SAN FRANCISCO (Reuters Health) Sept 28 - Long-term care facilities with high rates of urinary tract infections (UTI) caused by quinolone-resistant Escherichia coli may represent a “reservoir of risk” for patients in acute care facilities, researchers from Vancouver, British Columbia reported Wednesday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Lead investigator Leanne Kwan, clinical pharmacist at St. Paul’s Hospital, and associates noticed an overuse of ciprofloxacin within the facilities of a large integrated healthcare organization. They also noticed an increase in resistant UTIs, which prompted a retrospective study to identify patterns of transmission, the antibiotic selection process and possible resistance patterns in these populations.

Evaluation of the records for a 1-year period for about 800 patients in acute and long-term care facilities in the Providence Health Care system revealed positive urine cultures in 130 patients, Kwan told Reuters Health.
This is a part of article Cipro side effects, by Deborah Mitchell Taken from "Generic Cipro (Ciprofloxacin) Information" Information Blog